Company news
Argenica Therapeutics Ltd (ASX:AGN) news
Argenica Therapeutics Ltd news releases on 6ix. Latest, Aug 26, 2026: Appendix 4E & Annual Report to 30 June 2026
Press releases & updates
Appendix 4E & Annual Report to 30 June 2026
August 26, 2026
ARG007 Shows Significant Neuroprotection in Concussion Study
July 15, 2026
ARG007 (Xaranetide) Completes All Three FDA Requested Assays
June 10, 2026
WHO Confirms Xaranetide as INN for ARG-007
June 9, 2026
IND Application Advanced With Successful Completion of Assay
May 20, 2026
Clinical Advisory Committee Established to Advance Phase 2b
May 13, 2026
Presentations at European Stroke Organisation Conference
March 25, 2026
Argenica Receives $3.97m R&D Tax Incentive Cash Rebate
March 16, 2026
Half Yearly Report and Accounts
February 10, 2026
Successful Applicaton for EMA Paediatric Waiver
February 1, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 27, 2026
Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients
December 18, 2025
AI Analysis Reveals Efficacy In Severe Stroke Patients
December 10, 2025
Positive TNK Study Results Fulfil Key FDA Requirement
December 3, 2025
ARG-007 Efficacious Dose Validated in New Preclinical Study
November 24, 2025
Phase 2 Trial Promising Improvements in Functional Outcomes
October 14, 2025
Topline Phase 2 Trial Results of ARG-007 in AIS Patients
September 2, 2025
Trading Halt
August 31, 2025
Appendix 4E & Annual Report to 30 June 2025
August 28, 2025
Argenica Receives IND Feedback From FDA
August 13, 2025
Argenica Awarded Federal Government Funding
June 20, 2025
Argenica to Progress Clinical Development in TBI
June 17, 2025
Update on Investigational New Drug Application
June 9, 2025
New US Patent for Surgical Stroke
May 21, 2025
Last Patient Dosed in Phase 2 Stroke Trial
April 10, 2025
Updated - Main TBI Injury Study Annoucement
February 3, 2025
ARG-007 Shows Significant Neuroprotection in Main TBI Study
February 3, 2025
Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
January 29, 2025
Phase 2 Stroke Clinical Trial Update
December 9, 2024
$2.76m R&D Tax Incentive Cash Rebate Received for FY24
November 20, 2024
Quarterly Activities/Appendix 4C Cash Flow Report - updated
October 31, 2024
FDA Grants ODD & RPDD for Second Drug in Treatment of HIE
October 30, 2024
Positive Results in Key IND Enabling Studies
September 25, 2024
Appendix 4E & Annual Report to 30 June 2024
August 28, 2024
ARG-007 Reduces Effects of TBI in Preclinical Study
May 14, 2024
DSMB Confirms Safety of First Patients Dosed
April 28, 2024
Argenica Successfully Completes $12.0m Placement
April 11, 2024
Patient Dosing Milestone Achieved in Phase 2 Stroke Trial
April 9, 2024
First Patient Dosed in Phase 2 Stroke Trial of ARG-007
March 27, 2024
FDA Grants Rare Pediatric Disease Designation For HIE
March 24, 2024
Phase 2 Manufacturing Completed & Trial Update
February 11, 2024
Appointment of Non-Executive Chair
November 29, 2023
FDA Grants Orphan Drug Designation for ARG-007 HIE Treatment
November 15, 2023
Argenica Receives $2.09m R&D Tax Incentive Cash Rebate
November 12, 2023
ARG-007 Inhibits Cause of Alzheimer's in Pre-Clinical Study
November 2, 2023
Preclinical HIE Study - ARG007 Effective Stand-Alone Therapy
October 17, 2023
Ethics Approval Received for Phase 2 Trial
September 11, 2023
Grant Awarded To Develop Additional Administration Route
September 11, 2023
Positive FDA Feedback Following Pre-Ind Meeting
August 22, 2023
Appendix 4E & Annual Report 30 June 2023
August 22, 2023